Drugmakers hope to export their success to emerging markets so they can reap big rewards, but Johnson & Johnson's Janssen unit appears to have taken a backward approach in South Korea, where it is in hot water over a recall of Children's Tylenol products.
In September, the generics subsidiary of Endo Health Solutions voluntarily recalled one lot of two pain drugs that it called "super potent" because both exceeded their prescribed weights. Now Endo has added 100 more lots to that removal.
Drugmakers, get ready to revise your playbooks. Branded generics may be a no-go in India. Continuing their assault on drug costs, government officials are rolling out a new generics-only licensing policy. New off-patent drugs would win approval under their generic names only.
Reuters reports on a new study that ties excessive use of the painkiller acetaminophen (Tylenol) to an increased risk of blood cancers. Then, in the second paragraph, the story reflects some of the
Tylenol maker Johnson & Johnson will revamp its product line for infants and children to help prevent overdoses of the pain and fever remedy. The company plans to make all children's Tylenol
FDA has issued an ultimatum to makers of combination painkillers such as Percocet and Vicodin. The agency won't ban the drug as an advisory panel recommended in 2009, the New York Times reports, but
Johnson & Johnson has long been a case study for crisis managers everywhere. Remember the Tylenol scare back in the early '80s? Ever since, J&J has drawn kudos for its quick-and-thorough
Here's a ban that could be a real pain for drugmakers: An FDA advisory panel voted in favor of pulling the narcotic combo drugs Percocet and Vicodin, seven other acetaminophen/narcotic combos, and
Drugmakers should limit doses and strengthen warnings on Johnson and Johnson's Tylenol and other medicines containing acetaminophen to reduce the risk of liver injury, according to a U.S. report.